Belite Bio, Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BLTE Nasdaq 2836 www.belitebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Belite Bio, Inc

Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE) - Jan 21st, 2025 11:31 am
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 - Nov 27th, 2024 8:00 am
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Nov 12th, 2024 6:00 am
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results - Nov 5th, 2024 1:00 pm
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds - Nov 3rd, 2024 9:00 pm
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - Oct 14th, 2024 12:00 pm
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit - Oct 8th, 2024 12:00 pm
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Sep 26th, 2024 12:51 pm
Here's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn Situation - Sep 24th, 2024 1:28 pm
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 - Sep 19th, 2024 6:30 am
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease - Sep 10th, 2024 12:00 pm
Belite Bio to Participate in Three Upcoming Investor Conferences - Sep 3rd, 2024 12:00 pm
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer - Sep 1st, 2024 12:00 pm
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - Aug 9th, 2024 8:30 pm
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Aug 8th, 2024 12:00 pm
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results - Aug 5th, 2024 11:10 pm
Belite Bio to Present at the JonesHealthcare Seaside Summit - Jul 8th, 2024 12:00 pm
Estimating The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE) - Jun 17th, 2024 11:04 am
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan - Jun 12th, 2024 6:55 am
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference - May 14th, 2024 12:00 pm